MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients. To date, we have developed and validated novel biomarker signatures for PARPi and CKD4/6i.

Feel free to request meeting to learn more about MNM Diagnostics during BiO€QUITY Europe conference on 17-19 May 2021

More news